Skip to main content
Clinical Trials/NCT02317601
NCT02317601
Completed
Phase 4

Preoperative Single-high Dose Glucocorticoid for Patients Undergoing Hip Fracture Surgery and the Effect on Postoperative Delirium.

Hvidovre University Hospital1 site in 1 country122 target enrollmentDecember 2014

Overview

Phase
Phase 4
Intervention
methylprednisolone sodium succinate
Conditions
Delirium - Postoperative
Sponsor
Hvidovre University Hospital
Enrollment
122
Locations
1
Primary Endpoint
Post operative delirium measured with Confusion Assessment Method severity measure CAM-S
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The Study is a double-blinded, randomized, placebo-controlled trials. The Objective is to investigate the effect of single-high-dose glucocorticoid on surgical stress response and postoperative delirium among Elderly hip Fracture Patients undergoing surgery.

Detailed Description

Patients with Hip Fracture are exposed for two traumas that can trigger a stress response. The first is the fall that causes the Fracture. The second is the surgery. In this study the intervention is dispensed early in the disease course - as soon as the Fracture has been diagnosed and booked for surgery.

Registry
clinicaltrials.gov
Start Date
December 2014
End Date
May 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Christopher Clemmesen

MD

Hvidovre University Hospital

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing surgery for hip fracture
  • Informed signed consent
  • Danish speaking

Exclusion Criteria

  • Allergies towards contents of Solu-Medrol
  • Insulin dependent diabetes
  • In treatment for cancer disease
  • Positive HIV, Hepatitis b or C status
  • Lack of informed consent (eq. Severe dementia, coma, and others)
  • Current treatment with systemic glucocorticoids (pr.os or intravenous) Immunoinflammatory disease (Except topical treated skin disease and respiratory disease)
  • Current Immunosuppressive treatment
  • Unable to participate in CAM-S measurement
  • Peptic ulcera

Arms & Interventions

Methylprednisolone sodium succinate

125 mg iv, as single dose, preoperative.

Intervention: methylprednisolone sodium succinate

physiological saline

5 mL of Sodium-Chloride 9 mg/ml, Fresenius Kabi

Intervention: placebo saline

Outcomes

Primary Outcomes

Post operative delirium measured with Confusion Assessment Method severity measure CAM-S

Time Frame: 3 first post operative days

Post operative delirium measured with Confusion Assessment Method severity measure CAM-S

Secondary Outcomes

  • Post operative delirium incidents measured by CAM-S(3 days)
  • Patient mobility measured by Cumulated Ambulation Score (CAS)(3 first operative days)
  • The degree of inflammatory response measured by biomarker in the blood (suPAR, Interleukin 6, and others)(4 days)
  • Post operative Fatigue measured with a patient fatigue self-assessment 0-4. (Verbal rating scale) 0=no fatigue, 1=mild, 2 = moderate, 3 = severe, 4 = excruciating (in bed because of fatigue).(3 first postoperative days)
  • Psychiatric medications (total amount/use of psychiatric medications)(3 post-OR days)
  • Postoperative infections (numbers of patients with postoperative infections)(21 days)
  • Length of stay in hospital(21 days)

Study Sites (1)

Loading locations...

Similar Trials